Physician profile
Thomas E Calk
NPI 1629024492
$578.72
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $125 · 2021: $54.50 · 2022: $20.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $108.86 | 2019-2020 | |
| Biofire Diagnostics, LLC | $99.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.39 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $48.35 | 2019 | |
| Pfizer INC. | $47.49 | 2019-2022 | |
| Shire North American Group INC | $34.60 | 2019 | |
| Sanofi Pasteur INC. | $33.09 | 2020-2021 | |
| Tris Pharma INC | $32.14 | 2019-2020 | |
| Kaleo, INC. | $29.05 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.87 | 2021 | |
| Vertical Pharmaceuticals, LLC | $16.89 | 2019 | |
| Cranial Technologies, INC | $15.89 | 2019 | |
| Glaxosmithkline, LLC. | $14.93 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.95 | 2019 | |
| Adlon Therapeutics L.P. | $11.85 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Calk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.